Research programme: Alzheimer's disease therapies - Alzhyme

Drug Profile

Research programme: Alzheimer's disease therapies - Alzhyme

Alternative Names: ANA-1; ANA-5

Latest Information Update: 06 Dec 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alzhyme
  • Developer Alzhyme; ANSTO Radiopharmaceuticals and Industrials; CSIRO
  • Class Peptides; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 16 Apr 2010 Preclinical development is ongoing In Australia
  • 05 Sep 2006 This programme is still in active development
  • 27 Jul 2004 This programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top